



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/913,967

12/31/2001

Wilhelmus Evergardu Hennink

313632001000

8024

25225 7590 10/02/2008

MORRISON & FOERSTER LLP
12531 HIGH BLUFF DRIVE
SUITE 100
SAN DIEGO, CA 92130-2040

EXAMINER

FUBARA, BLESSING M

ART UNIT

PAPER NUMBER

1618

MAIL DATE

DELIVERY MODE

10/02/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 09/913,967	Applicant(s) HENNINK ET AL.	
	Examiner BLESSING M. FUBARA	Art Unit 1618	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 25 June 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,7,13,15-17,24 and 27-31 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,7,13,15-17,24 and 27-31 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Examiner acknowledges receipt of request for extension of time, request for consideration under 37 CFR 1.114, Terminal disclaimer filed 6/25/08; amendment and remarks filed 4/25/08. Claims 2, 6 and 12 are canceled. Claims 1, 7, 13 and 15 are amended. Claims 1, 7, 13, 15-17, 24 and 27-31 are pending.

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/25/08 has been entered.

Response to Arguments

Previous rejections that are not reiterated herein are withdrawn.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any

Art Unit: 1618

evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 1, 7 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Li et al. ("Biodegradable brush-like polymers from poly(D, L-lactide) or poly(D, L-lactide-co-glycolide) and charge-modified, hydrophilic dextrans as backbone - synthesis, characterization and in vitro degradation properties," in *Polymer* **38** (1997), pp. 6197–6206) or Li et al.

("Biodegradable brush-like polymers from poly(D, L-lactide) or poly(D, L-lactide-co-glycolide) and charge-modified, hydrophilic dextrans as backbone -in-vitro degradation and controlled release of hydrophilic macromolecules. *Polymer* **39** (1998), pp. 3087–3097).

5. Li in either reference, Vol. 39 or Vol. 38 describes poly D,L lactide grafted dextran (see the entire document with emphasis on the abstract, and experimental section). Li does not disclose that the separate forms, the L-lactide grafted form of dextran and the D-lactide grafted form of dextran are combined to form the composition of claim 1. However, the combination of the L-lactide grafted form and the D-lactide grafted form of dextran reads on the D,L lactide grafted dextran. Specifically, claim 1 does not indicate any special ratios of the L-lactide dextran to the D-lactide dextran that may have provided some difference between the claimed and the disclosed. Li's disclosure of lactide grafted dextran meets the dispersible hydrophilic polymer and the dextran of claims 1 and 7. Regarding claim 13, the artisan has the ability of using incorporating appropriate number of lactide monomers that would lead to the desired lactide grafted polymer that would encapsulate and degrade to release hydrophilic molecules. Since the D,L- form contains the D- and L-forms, one having ordinary skill in the art at the time

Art Unit: 1618

the invention was made would have reasonable expectation that grafted the dextran with the D,L-form of the lactide or combining the D- or L-lactide grafted forms of the dextran would provide the anticipated in vitro degradation of the polymer or in vitro degradation and controlled releases of hydrophilic molecules such the degradation to release of protein or peptides (abstract; pages 3087, 3094, at least). The language of the composition is comprising such that the D,L-lactide grafted form of the dextran meets the L-lactide and D-lactide grafted dextran. In the absence of unexpected result, a composition that comprises D, L-lactide grafted dextran that is a combination of L-lactide grafted dextran and D-lactide grafted dextran is not inventive over a D,L-lactide grafted dextran.

6. Claims 1, 7, 13, 24 and 29-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Li et al. (“Biodegradable brush-like polymers from poly(D, L-lactide) or poly(D, L -lactide-co-glycolide) and charge-modified, hydrophilic dextrans as backbone — in-vitro degradation and controlled release of hydrophilic macromolecules. *Polymer* **39** (1998), pp. 3087–3097).

7. Li describes poly D,L lactide grafted dextran (see the entire document with emphasis on the abstract, and experimental section). Li does not disclose that the separate forms, the L-lactide grafted form of dextran and the D-lactide grafted form of dextran are combined to form the composition of claim 1. However, the combination of the L-lactide grafted form and the D-lactide grafted form of dextran reads on the D,L lactide grafted dextran. Specifically, claim 1 does not indicate any special ratios of the L-lactide dextran to the D-lactide dextran that may have provided some difference between the claimed and the disclosed. Li's disclosure of lactide grafted dextran meets the dispersible hydrophilic polymer and the dextran of claims 1 and 7. Regarding claim 13, the artisan has the ability of using incorporating appropriate number of lactide monomers that would lead to the desired lactide grafted polymer that would encapsulate

Art Unit: 1618

and degrade to release hydrophilic molecules. Li prepares the lactide grafted dextran as microspheres (abstract; page 6198) meeting claim 29; the protein such as BSA (abstract and pages 3093 and 3094) that can be released from the grafted polymer meets claims 30 and 31. Since the D,L- form contains the D- and L-forms, one having ordinary skill in the art at the time the invention was made would have reasonable expectation that grafted the dextran with the D,L- form of the lactide or combining the D- or L-lactide grafted forms of the dextran would provide the anticipated in vitro degradation or the polymer or in vitro degradation and controlled releases of hydrophilic molecules such the degradation to release of protein or peptides (abstract; pages 3093, 3094, at least). While Li does not say that the microspheres formulation is a hydrogel, lactide and dextran hydrogels are known in the art and the artisan would formulate composition as a hydrogel as evidenced by the abstract, column 2, lines 6-8 of US 4,814,182. In the absence of unexpected result, a composition that comprises D, L-lactide grafted dextran that is a combination of L-lactide grafted dextran and D-lactide grafted dextran is not inventive over a D,L-lactide grafted dextran. Because the claims use the language of comprising, the D,L-lactide grafted form of the dextran meets the L-lactide and D-lactide grafted dextran.

8. Claims 15-17, 27 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Li et al. Li et al. ("Biodegradable brush-like polymers from poly(D, L-lactide) or poly(D, L-lactide-co-glycolide) and charge-modified, hydrophilic dextrans as backbone — synthesis, characterization and in vitro degradation properties," in *Polymer* **38** (1997), pp. 6197–6206) in view of Jarret et al. (US 4,788,979) or Bays et al. (US 4,650,488).

9. Li discloses preparation of D,L lactide grafted dextran (see the whole document with emphasis on the abstract; pages 6198, 6199, 6202, 6204). Li suggests that molecules such as

Art Unit: 1618

peptides and proteins have been known to be delivered by lactide polymers (page 6197) meeting claims 27 and 28. Li prepares the lactide grafted dextran using D, L-lactide and since the D,L-form contains the D- and L-forms, one having ordinary skill in the art at the time the invention was made would have reasonable expectation that grafted the dextran with the D,L-form of the lactide or combining the D- or L-lactide grafted forms of the dextran would provide the anticipated in vitro degradation of the polymer or in vitro degradation and controlled releases of hydrophilic molecules such as the degradation to release of protein or peptides (abstract; pages 6193, 6194, at least). While Li is silent that the formulation is a hydrogel, lactide and dextran hydrogels are known in the art and the artisan would formulate composition as a hydrogel as evidenced by the abstract, column 2, lines 6-8 of US 4,814,182. Selection of any order of performing the process steps is prima facie obvious in the absence of new or unexpected results as it regards the sequence of steps 15 a) to 15 e). Li does not teach the use of the initiators as recited in claims 15 and 16. However, lauryl alcohol, meeting the limitation of the initiator in claims 15 and 16, is known in the art for initiating polymerization of polyesters such as lactides, glycolides and caprolactones as evidenced by column 5, line 6 of US 4,650,488 and columns 5 and 6 legends of Tables IA and B. Therefore, taking the teachings of the prior art, one having ordinary skill in the art at the time the invention was made would have reasonable expectation of success that lauryl alcohol would initiate the reaction between the lactide for grafting onto the dextran for the production of the lactide grafted dextran for the delivery of active drugs such as proteins and peptides.

No claim is allowed

Art Unit: 1618

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BLESSING M. FUBARA whose telephone number is (571)272-0594. The examiner can normally be reached on 7 a.m. to 5:30 p.m. (Monday to Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Blessing M. Fubara/
Examiner, Art Unit 1618